Macrophage membrane-biomimetic adhesive polycaprolactone nanocamptothecin for improving cancer-targeting efficiency and impairing metastasis
Bioactive Materials
; 20:449-462, 2023.
Article
in English
| Scopus | ID: covidwho-2246587
ABSTRACT
The recent remarkable success and safety of mRNA lipid nanoparticle technology for producing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines has stimulated intensive efforts to expand nanoparticle strategies to treat various diseases. Numerous synthetic nanoparticles have been developed for pharmaceutical delivery and cancer treatment. However, only a limited number of nanotherapies have enter clinical trials or are clinically approved. Systemically administered nanotherapies are likely to be sequestered by host mononuclear phagocyte system (MPS), resulting in suboptimal pharmacokinetics and insufficient drug concentrations in tumors. Bioinspired drug-delivery formulations have emerged as an alternative approach to evade the MPS and show potential to improve drug therapeutic efficacy. Here we developed a biodegradable polymer-conjugated camptothecin prodrug encapsulated in the plasma membrane of lipopolysaccharide-stimulated macrophages. Polymer conjugation revived the parent camptothecin agent (e.g., 7-ethyl-10-hydroxy-camptothecin), enabling lipid nanoparticle encapsulation. Furthermore, macrophage membrane cloaking transformed the nonadhesive lipid nanoparticles into bioadhesive nanocamptothecin, increasing the cellular uptake and tumor-tropic effects of this biomimetic therapy. When tested in a preclinical murine model of breast cancer, macrophage-camouflaged nanocamptothecin exhibited a higher level of tumor accumulation than uncoated nanoparticles. Furthermore, intravenous administration of the therapy effectively suppressed tumor growth and the metastatic burden without causing systematic toxicity. Our study describes a combinatorial strategy that uses polymeric prodrug design and cell membrane cloaking to achieve therapeutics with high efficacy and low toxicity. This approach might also be generally applicable to formulate other therapeutic candidates that are not compatible or miscible with biomimetic delivery carriers. © 2022 The Authors
camptothecin; firtecan; irinotecan; isoflurane; Ki 67 antigen; lipid nanoparticle; lipopolysaccharide; penicillin derivative; polycaprolactone; streptomycin; animal model; animal tissue; antineoplastic activity; Article; breast cancer; cancer therapy; cell membrane; cytotoxicity assay; drug delivery system; drug distribution; drug efficacy; drug formulation; drug release; fluorescence imaging; fluorescence microscopy; histopathology; lung metastasis; M1 macrophage; macrophage; metastasis; mononuclear phagocyte; nanoencapsulation; nanomedicine; nonhuman; particle size; photon correlation spectroscopy; real time polymerase chain reaction; transmission electron microscopy; TUNEL assay; Antimetastasis; Cancer nanomedicine; Macrophage membrane; Nanocamptothecin; Polymer prodrug
Full text:
Available
Collection:
Databases of international organizations
Database:
Scopus
Language:
English
Journal:
Bioactive Materials
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS